SXTC

+ Watchlist + Portfolio

China SXT Pharmaceuticals, Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.96
52-Week Range: $1.78 – $83,760.00
Market Cap: $3.18M
P/E (TTM): —
EPS (TTM): -730.40
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.00
PEG Ratio: —
Return on Equity: -27.49%
Return on Assets: -15.78%
Gross Margin: 21.85%
Operating Margin: -153.28%
Profit Margin: 0.00%
Current Ratio: 7.93
Debt/Equity: 0.04
Total Debt: $1.12M
Free Cash Flow: $-4.74M
Revenue Growth: -43.90%
Earnings Growth: —
Enterprise Value: $-26.23M

SXTC Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$1.97M	$1.93M	$1.74M	$1.14M
Cost of Revenue	$1.55M	$1.37M	$1.37M	$889.35K
Gross Profit	$426.27K	$553.97K	$367.43K	$248.70K
Selling, General & Admin	$6.03M	$3.07M	$3.05M	$7.37M
Operating Expenses	$6.03M	$3.07M	$3.05M	$7.37M
Operating Income	-$5.61M	-$2.52M	-$2.68M	-$7.12M
EBITDA	-$5.21M	-$2.28M	-$2.50M	-$6.00M
Pretax Income	-$5.93M	-$3.10M	-$3.30M	-$6.21M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$5.93M	-$3.10M	-$3.30M	-$6.21M
Diluted EPS	-1483693.00	-134718.78	-2882.77	—
Diluted Shares	4	23	1146	—

SXTC Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$17.37M	$12.07M	$18.10M	$28.18M
Receivables	$1.58M	$1.35M	$1.90M	$3.23M
Inventory	$531.25K	$794.86K	$828.05K	$777.06K
Current Assets	$19.52M	$14.23M	$21.30M	$34.51M
Total Assets	$29.55M	$23.13M	$21.66M	$34.75M
Current Liabilities	$14.50M	$8.90M	$6.01M	$4.35M
Long-Term Debt	$117.86K	$117.13K	$96.26K	$644.39K
Total Debt	$3.76M	$2.65M	$983.88K	$1.12M
Total Liabilities	$14.86M	$9.20M	$6.22M	$5.05M
Retained Earnings	-$21.61M	-$24.71M	-$28.02M	-$34.22M
Shareholders' Equity	$14.69M	$13.93M	$15.44M	$29.71M
Working Capital	$5.02M	$5.33M	$15.28M	$30.16M

SXTC Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$80.76K	-$1.93M	-$2.35M	-$4.02M
Capital Expenditure	-$70.68K	-$7.06K	-$2.02K	-$1.25M
Free Cash Flow	-$151.44K	-$1.94M	-$2.35M	-$5.27M
Depreciation & Amortisation	$250.16K	$273.07K	$151.64K	$143.22K
Stock-Based Compensation	$554.57K	$352.10K	$0.00	$5.31M
Investing Cash Flow	-$12.30K	$26.42K	$63.52K	-$1.25M
Financing Cash Flow	$2.94M	-$2.62M	$8.40M	$14.43M
Net Change in Cash	$2.85M	-$4.53M	$6.12M	$9.17M

SXTC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q3 2025	Q1 2026
Cash & Equivalents	$18.10M	$21.17M	$28.18M
Receivables	$1.90M	$2.87M	$3.23M
Inventory	$828.05K	$751.35K	$777.06K
Current Assets	$21.30M	$26.04M	$34.51M
Total Assets	$21.66M	$26.35M	$34.75M
Current Liabilities	$6.01M	$5.96M	$4.35M
Long-Term Debt	$96.26K	$73.10K	$644.39K
Total Debt	$983.88K	$1.20M	$1.12M
Total Liabilities	$6.22M	$6.12M	$5.05M
Retained Earnings	-$28.02M	-$34.38M	-$34.22M
Shareholders' Equity	$15.44M	$20.23M	$29.71M
Working Capital	$15.28M	$20.08M	$30.16M

Market Snapshot

About

China SXT Pharmaceuticals is a pharmaceutical company engaged in the research, development, manufacture, and sale of traditional Chinese medicine and chemical medicine products. The company focuses on botanical drugs and innovative drug development targeting cardiovascular, oncology, and other therapeutic areas. It operates manufacturing facilities in China.